^
    Back
    Association details:
    Biomarker:KRAS mutation + BCL2A1 overexpression
    Cancer:Acute Myelogenous Leukemia
    Drug:Venclexta (venetoclax) (Bcl2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2018
    Title:

    Biomarkers Predicting Venetoclax Sensitivity and Strategies for Venetoclax Combination Treatment

    Published date:
    11/01/2018
    Excerpt:
    Samples with KRAS mutations demonstrated high BCL2A1 expression, which potentially mediate venetoclax resistance.
    DOI:
    https://doi.org/10.1182/blood-2018-175